NCT01352962已完成1 期
A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- dose limiting toxicity (DLT)
研究概览
简要总结
Background:
- Gemcitabine and carboplatin are chemotherapy drugs used to treat several types of cancer, including cancer of the pancreas, bladder, ovaries, and lung. Lenalidomide, a drug that prevents the growth of new blood vessels in tumors, has been approved for treatment of certain blood cancers, but it has not yet been approved for use in combination with gemcitabine and carboplatin. Researchers are interested in determining the safest and most effective dose of this combined form of chemotherapy for solid tumors, particularly for urothelial cancer (tumors of the bladder, urethra, ureter, or renal pelvis).
Objectives:
- To evaluate the safety and effectiveness of combined lenalidomide, gemcitabine, and carboplatin as a treatment for solid tumor cancers.
- To evaluate the safety and effectiveness of combined lenalidomide, gemcitabine, and carboplatin as a treatment for urothelial (bladder) cancer.
Eligibility:
- Individuals at least 18 years of age who have been diagnosed with solid tumors that have not responded to standard treatments.
- Individuals at least 18 years of age who have been diagnosed with urothelial cancer that has not responded to standard treatments.
Design:
- Participants will be screened with a physical examination, medical history, blood tests, and tumor imaging studies.
- Participants with urothelial cancer will receive lenalidomide alone for the first 14 days of a 21-day cycle before starting the first full treatment cycle.
- All participants will receive gemcitabine on days 1 and 8, and carboplatin on day 1 only, of every 21-day treatment cycle. Lenalidomide will be taken daily at home for the first 14 days of each cycle. Participants will be asked to take aspirin or other medications to prevent the possibility of blood clots.
- Participants may receive up to six cycles of treatment with this combination. If after six cycles the cancer has not grown or has shrunk, participants may continue to take lenalidomide alone for an additional 6 months (total of 12 months of therapy) or until the cancer recurs.
- Participants will be monitored with blood samples, physical examinations, and tumor imaging studies through the cycles of treatment.
- After the end of the last treatment cycle, participants will have followup visits every 3 months for the next 18 months, then every 6 months for another 18 months, and then yearly.
详细描述
BACKGROUND:
- Gemcitabine plus carboplatin is an accepted first-line therapy in patients unfit for cisplatin chemotherapy with metastatic urothelial carcinoma or other solid tumor malignancies.
- Both non-clinical and clinical data support targeting angiogenesis in urothelial carcinoma and other solid tumors.
- Both non-clinical and clinical data support targeting the immune system in urothelial carcinoma and other solid tumors.
- Lenalidomide has both anti-angiogenic and potent immunomodulatory properties.
- Lenalidomide has been safely coadministered with cytotoxic therapy in patients with solid tumors and non-clinical studies demonstrate possible synergy with gemcitabine.
OBJECTIVES:
Primary
- To establish the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of lenalidomide which can be safely combined with gemcitabine and carboplatin in patients with advanced/metastatic UC and other solid tumors that are unfit for cisplatin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •INCLUSION CRITERIA:
- •Dose Escalation cohort only
- •- Adult patients with histologic documentation of an advanced solid tumor for whom gemcitabine and carboplatin would be appropriate first line therapy, including but not limited to urothelial cancer, non-small cell lung cancer, pancreatic and ovarian carcinoma.
- •Expansion cohort only
- •Patients must have a histologically confirmed diagnosis of urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis. Confirmation may be obtained from any CLIA certified lab.
- •Patient must have a histologically confirmed diagnosis of non-transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis including but not limited to squamous cell, neuroendocrine, adenocarcinoma including urachal and sarcomatoid. Confirmation may be obtained from any CLIA certified lab.
- •All patients
- •Unresectable or metastatic disease
- •Urothelial cancer patients should be ineligible for cisplatin based on one or more of the following:
- •Calculated creatinine clearance of < 60 mL/min (but greater than or equal to 30 mL/min)
- •Solitary kidney
- •Karnofsky Performance Status < 80%
- •Age greater than or equal to 18 years of age; UC is not a common cancer in children and without proven benefit, this combination of chemotherapy agents presents too great a risk for conducting as a phase I study in children.
- •Karnofsky Performance Status greater than or equal to 60%
- •Required Initial Laboratory Values:
- •Absolute neutrophil count greater than or equal to 1.2 x 10(9)/L
- •Platelets greater than or equal to 100 x 10(9)/L
- •Bilirubin less than or equal to 1.5 times the upper limit of normal for the institution or less than or equal to 3 mg/dl in a subject with Gilbert Syndrome
- •Aspartate transaminase (AST) and alanine transaminase (ALT) less than or equal to 3 times the ULN for the institution (less than or equal to 5 times the ULN is acceptable if liver has tumor involvement).
- •Serum creatinine < 2 or calculated creatinine clearance (CrCl) greater than or equal to 30 mL/min
- •Ability to understand and willingness to sign the written informed consent document.
- •Patients must be able to swallow whole capsules. Capsules must not be crushed or chewed; capsules must not be opened.
排除标准
- •For urothelial cancer patients, no prior combination systemic chemotherapy for metastatic disease, except:
- •Single-agent radiosensitizing chemotherapy is not considered prior systemic therapy
- •Prior neoadjuvant or adjuvant systemic chemotherapy (including cisplatin-based) is allowed provided it was completed greater than or equal to 6 months prior to the diagnosis of metastatic disease
- •Prior intravesical therapy is permitted
- •For non-urothelial cancer patients, no more than 1 prior line of combination systemic chemotherapy for metastatic disease is allowed
- •Less than or equal to 2 weeks since radiation therapy
- •Unstable angina
- •New York Heart Association (NYHA) Grade II or greater congestive heart failure
- •History of myocardial infarction within 6 months
- •History of stroke within 6 months
- •Clinically significant peripheral vascular disease
- •Evidence of bleeding diathesis or coagulopathy. Patients that are on anticoagulation therapy for DVT will be allowed to enroll and continue on the treatment dose of enoxaparin or other anticoagulation such a warfarin.
- •Patients with contraindications to anticoagulation therapy for deep venous thrombosis such as:
- •Patients on full treatment dose of anticoagulation such as those patients being treated for a deep vein thrombosis or pulmonary embolus.
- •Presence of central nervous system or brain metastases
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1
- •Anticipation of need for major surgical procedure during the course of the study
- •Those patients that develop DVTs during the study will be treated with anticoagulants and in certain cases, will continue on the protocol.
- •Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 14 days and again within 24 hours prior to starting Cycle 1 of lenalidomide. Further, they must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP, even if they have had a successful vasectomy. A FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
- •Inability to comply with study and/or follow-up procedures
- •Patients may not be receiving any other investigational agents
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide, gemcitabine or carboplatin, or other agents used in study.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Due to the possibility of infection reactivation, patients who are known seropositive for or who have active viral infection with human immunodeficiency virus (HIV) are NOT eligible.
- •INCLUSION OF WOMEN AND MINORITIES:
- •Both men and women of all races and ethnic groups are eligible for this trial.
研究组 & 干预措施
Arm 1
Experimental
Standard of Care plus escalating doses of Lenalidomide
干预措施: Gemcitabine (Drug)
Arm 1
Experimental
Standard of Care plus escalating doses of Lenalidomide
干预措施: Carboplatin (Drug)
Arm 2
Experimental
Lenalidomide Lead for 14 days + standard of care + lenalidomide MTD
干预措施: Carboplatin (Drug)
Arm 1
Experimental
Standard of Care plus escalating doses of Lenalidomide
干预措施: Lenalidomide (Drug)
Arm 2
Experimental
Lenalidomide Lead for 14 days + standard of care + lenalidomide MTD
干预措施: Gemcitabine (Drug)
Arm 2
Experimental
Lenalidomide Lead for 14 days + standard of care + lenalidomide MTD
干预措施: Lenalidomide (Drug)
结局指标
主要结局
dose limiting toxicity (DLT)
时间窗: Maximum Tolerated Dose (MTD)
any grade 3 or 4 toxicity with exceptions listed in protocol; MTD is one dose level below the dose that induces DLT in more than 1/6 patients
次要结局
- overall survival(every 3 months for the first 18 months, every 6 months for the subsequent 18 months, then yearly)
- response rate(every 3 months for the first 18 months, every 6 months for the subsequent 18 months, then yearly)
- progression free survival(every 3 months for the first 18 months, every 6 months for the subsequent 18 months, then yearly)
- effects of treatment on Treg, sIL-2R, VEGF, CTC and CEC(baseline, lead-in day 8, lead-in day 14 and C1D8)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung CancerLung CancerNCT00016315Radiation Therapy Oncology Group35
终止
2 期
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder CancerBladder CancerNCT01916109Memorial Sloan Kettering Cancer Center4
尚未招募
不适用
Phase I study of gemcitabine and carboplatin plus sorafenib in patients with advanced solid tumorsadvanced solid tumors10027655CancerNL-OMON31053Antoni van Leeuwenhoek Ziekenhuis28
已完成
1 期
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological CancerLeydig Cell TumorOvarian SarcomaOvarian Stromal CancerRecurrent Cervical CancerRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Ovarian Germ Cell TumorRecurrent Primary Peritoneal Cavity CancerRecurrent Uterine SarcomaRecurrent Vaginal CancerRecurrent Vulvar CancerPseudomyxoma PeritoneiNCT01652794Case Comprehensive Cancer Center12
已完成
2 期
Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder CancerGallbladder CancerCholangiocarcinomaNCT00660140Washington University School of Medicine49